Blog
RSS FeedPosted by Michael Wonder on 11 Jan 2023
Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with advanced, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 04 Jan 2023
Mobocertinib succinate for patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer after platinum-based chemotherapy
4 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 22 Dec 2022
NICE recommends a weekly injection for treating growth failure in children
22 December 2022 - This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments. ...
Posted by Michael Wonder on 20 Dec 2022
NICE recommends Enhertu for more people with advanced breast cancer
20 December 2022 - Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage ...
Posted by Michael Wonder on 15 Dec 2022
Avatrombopag maleate for the treatment of patients with primary chronic immune thrombocytopenia
15 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Esketamine hydrochloride for patients with treatment-resistant depression
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Trifluridine with tipiracil hydrochloride for the treatment of patients with metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after two or more treatments
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Pembrolizumab for the neo-adjuvant and adjuvant treatment of patients with early or locally advanced triple negative breast cancer
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Amivantamab for the treatment of patients with EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Cabozantinib maleate for patients with previously treated advanced hepatocellular carcinoma
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 14 Dec 2022
More than 5,200 people could benefit after NICE broadens recommendation on chronic lung disease treatment
14 December 2022 - NICE broadens recommendation on chronic lung disease treatment. ...
Posted by Michael Wonder on 08 Dec 2022
NICE recommends Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus refractory (with or without resistance) to prior therapies
8 December 2022 - Livtencity is the first and only oral treatment that inhibits CMV specific UL97 protein kinase and ...
Posted by Michael Wonder on 01 Dec 2022
Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer
1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 29 Nov 2022
Mepolizumab for the treatment of patients with severe chronic rhinosinusitis with nasal polyps
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 29 Nov 2022
Voclosporin with immunosuppressives for the treatment of patients with lupus nephritis
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...